Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | FRK | P42685 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22719310 | 0.87 | CAMKK2 (0.47) | MAP4K4EGFRFRKMAPK9CSNK1A1 | |
| SCHEMBL22719330 | 0.85 | SLC6A4 (0.47) | MAP4K4EGFRFRKMAPK9CSNK1A1 | |
| SCHEMBL8323880 | 0.81 | HCRTR1 (0.52) | CASP6KDM4CHCRTR1HCRTR2 | |
| SCHEMBL22728425 | 0.78 | KDM4C (0.54) | MAP4K4CSNK1A1CDK9JAK2MAPK14 | |
| SCHEMBL2645320 | 0.78 | MAPK14 (0.54) | MAPK14ADORA2B | |
| SCHEMBL22719444 | 0.78 | KMO (0.48) | MAP4K4EGFRFRKMAPK9CSNK1A1 | |
| SCHEMBL29453773 | 0.78 | KMO (0.48) | MAP4K4EGFRFRKMAPK9CSNK1A1 | |
| SCHEMBL25184191 | 0.76 | MAPK9 (0.47) | MAP4K4EGFRFRKMAPK9CSNK1A1 | |
| SCHEMBL15836282 | 0.75 | HCRTR1 (0.49) | CASP6KDM4CHCRTR1HCRTR2MAOB | |
| SCHEMBL6217549 | 0.75 | LMNA (0.45) | CDK9KMOMAPK14KDM4CHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0943616-B1 | Substituted imidazole derivatives and their use as cytokine inhibitors | SMITHKLINE BEECHAM CORP (US) | 2005-05-04 | — | — | EP | disclosed |
| US-6645989-B2 | Antiinflammatory agents | SMITHKLINE BEECHAM CORPORATION | 2003-11-11 | — | — | US | disclosed |
| US-20030064997-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-03 | — | — | US | disclosed |
| US-6268370-B1 | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-07-31 | — | — | US | disclosed |
| EP-0943616-A1 | Substituted imidazole derivatives and their use as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-22 | — | — | EP | disclosed |
| US-5916891-A | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-29 | — | — | US | disclosed |
| US-5686455-A | Imidazole derivatives and their use as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1997-11-11 | — | — | US | disclosed |
| US-5656644-A | CYTOKINE SUPPRESSORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0623126-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014081-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064997-A1 | Novel compounds | BRD4, BRDT, HDAC6 | MAP4K4 1484/4885EGFR 1530/4885FRK 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.